Contraceptive patch

Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution

Retrieved on: 
Wednesday, March 13, 2024
Contraceptive patch, Agile, Therapy, Loan

PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has paid-off the remainder of its debt facility with Perceptive Advisors (“Perceptive”).

Key Points: 
  • PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has paid-off the remainder of its debt facility with Perceptive Advisors (“Perceptive”).
  • This significant milestone completes the repayment schedule contemplated by the Loan Agreement between the Company and Perceptive, which originated in 2020 and ended as of March 11, 2024.
  • The Company remains focused on growing Twirla® and advancing the Company’s business plan.
  • “Eliminating the entirety of our debt with Perceptive is a pivotal moment for us, signaling our readiness to embrace new opportunities while continuing to execute our business plan and grow Twirla,” said Agile Chief Executive Officer and Chairperson Al Altomari.

Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
COGS, ATM, Agile, Net, Conference, GAAP, Growth, Woman, Therapy, Table, Second, Cryptocurrency, Clothing, Video game, Food delivery, Bank, Contraceptive patch, Corium, Pandia

ET

Key Points: 
  • ET
    PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today reported financial results for the three and nine months ended September 30, 2023, and provided a corporate update.
  • Twirla demand for the third quarter 2023 was 74,325 total cycles, a 33% increase from the second quarter 2023 and a 147% increase from the third quarter 2022.
  • Retail demand, which is the Company’s most profitable channel, was 40,196 total cycles in the third quarter 2023, a 13% increase from the second quarter 2023.
  • Non-retail demand for the third quarter 2023 was 34,129 total cycles and an increase of 71% from the second quarter 2023.

Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members

Retrieved on: 
Monday, June 26, 2023
Growth, City, Partnership, GPO, Therapy, Agile, Levonorgestrel, Patient, MMCAP, Pharmaceutical industry, Contraceptive patch

PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Twirla will become available to MMCAP Infuse Members effective July 1, 2023. The Company expects this increased availability to positively impact growth of demand and factory sales in the non-retail channel, which grew 20% and 15% respectively from the fourth quarter 2022 to first quarter 2023.

Key Points: 
  • Twirla (levonorgestrel and ethinyl estradiol) transdermal system will be made available nationwide to members of MMCAP Infuse, effective July 1, 2023
    PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Twirla will become available to MMCAP Infuse Members effective July 1, 2023.
  • “We expect to see accelerated growth in the Twirla non-retail channel by partnering with MMCAP Infuse, a national cooperative GPO for government facilities that provides contracts for healthcare products and services, including birth control products,” said Agile Therapeutics’ Chief Commercial Officer Amy Welsh.
  • MMCAP Infuse has over 26,000 member facilities in all 50 states, including state agencies, counties, cities, and school districts,.
  • This partnership with MMCAP Infuse reinforces Agile’s commitment to making Twirla available to as many patients as possible.

Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health

Retrieved on: 
Thursday, June 15, 2023
Health, Levonorgestrel, Growth, Therapy, FPA, Birth control, Contraceptive patch

PRINCETON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Twirla will become available through FPA Women’s Health. The Company expects this increased availability to positively impact growth of demand and factory sales in the non-retail channel, which grew 20% and 15% respectively from the fourth quarter 2022 to first quarter 2023.

Key Points: 
  • FPA Women’s Health is the largest independent family planning service network in the United States, and the Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now the exclusive patch dispensed within FPA clinics in California
    PRINCETON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Twirla will become available through FPA Women’s Health.
  • The Company expects this increased availability to positively impact growth of demand and factory sales in the non-retail channel, which grew 20% and 15% respectively from the fourth quarter 2022 to first quarter 2023.
  • As California’s leading provider of in-clinic and telehealth women’s healthcare, FPA Women’s Health has 24 locations throughout Los Angeles County and other regions across California.
  • “We are thrilled to be the exclusive patch dispensed within FPA’s California clinics, and we expect to tap into a significant proportion of Twirla’s target population through the FPA network,” says Chief Commercial Officer Amy Welsh, “a connection that was made with the help of our partners at Afaxys.”
    Agile continues to prioritize strategic partnerships that have the potential to efficiently and effectively grow Twirla while simultaneously allowing the Company to responsibly manage its operating expenses.

Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®

Retrieved on: 
Tuesday, June 13, 2023
Telehealth, Partnership, GoodRx, Retail, Woman, Channel, NHS Electronic Prescription Service, Patient, Growth, Therapy, Pharmaceutical industry, Contraceptive patch

PRINCETON, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX), a women's healthcare company, today announced an agreement with vitaCare Prescription Services, a wholly owned subsidiary of GoodRx, to expand patient access and streamline fulfillment for Twirla (levonorgestrel ethinyl estradiol) transdermal system. VitaCare is a technology and services platform that helps patients navigate key access barriers for branded medications.

Key Points: 
  • VitaCare is a technology and services platform that helps patients navigate key access barriers for branded medications.
  • “The agreement with vitaCare aligns with our strategy to utilize partnerships to efficiently grow Twirla while continuing to responsibly manage our operating expenses,” said Agile Therapeutics’ Chief Commercial Officer Amy Welsh.
  • Twentyeight Health is a telehealth company providing affordable access and convenience for reproductive and sexual health and recently acquired the platform assets for SimpleHealth.
  • The Company believes that the Twentyeight Health platform will provide an opportunity for more patients to learn about and access Twirla.

Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update

Retrieved on: 
Thursday, May 11, 2023
COGS, Table, Birth, Parenthood, Woman, GAAP, Agile, Planned Parenthood, ATM, Patient, Physician, Growth, Deliv, Therapy, Conference, Female, Video game, Birth control, Contraceptive patch

PRINCETON, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2023 and provided a corporate update.

Key Points: 
  • ET
    PRINCETON, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2023 and provided a corporate update.
  • Twirla demand for the first quarter 2023 was 45,036 total cycles, a 20% increase from the fourth quarter 2022 and a 170% increase from the first quarter 2022.
  • Twirla factory sales for the first quarter 2023 were 43,446 total cycles, remaining flat compared to the fourth quarter 2022 and a 158% increase from the first quarter 2022.
  • These results reflect the exclusion of the fair market value remeasurement of warrants of $1.7 million for the first quarter 2023, $3.3 million for the fourth quarter 2022 and $1.4 million for the first quarter 2022.

Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023

Retrieved on: 
Friday, April 28, 2023
Growth, Therapy, Contraceptive patch, Lunar phase, Video game, Clothing

PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary expectations for first quarter 2023 Twirla® demand, net revenue and operating expenses.

Key Points: 
  • PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary expectations for first quarter 2023 Twirla® demand, net revenue and operating expenses.
  • First Quarter 2023 Twirla Demand:
    Total demand is expected to surpass 45,000 total cycles, representing at least 20% growth from the fourth quarter 2022 and a single-quarter record.
  • March 2023 set a single-month record for total demand cycles and the Company expects the momentum to carry into the second quarter 2023.
  • First Quarter 2023 operating expenses (“OPEX”) are expected to be in the range of $8.3 to $8.8 million, a 5%-10% decrease compared to fourth quarter 2022.

Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 22, 2023
COGS, Table, Birth, Parenthood, Woman, GAAP, Agile, Planned Parenthood, ATM, Patient, Physician, Growth, Therapy, Conference, Female, Video game, Cryptocurrency, Lithium, Birth control, Pharmaceutical industry, Contraceptive patch

PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and twelve months ended December 31, 2022 and provided a corporate update.

Key Points: 
  • Fourth quarter and full year 2022 net revenue growth reflects improvements in the following key areas:
    Twirla demand for the fourth quarter was 37,452 total cycles, a 25% increase from the third quarter 2022.
  • Twirla factory sales for the fourth quarter were 43,230 total cycles, a 31% increase from the third quarter 2022.
  • Fourth quarter GAAP operating expenses were $9.2 million for 2022, a decrease of 55% from the $20.3 million reported for the third quarter 2022.
  • Fourth quarter Non-GAAP operating expenses for 2022 were $9.2 million and remained substantially unchanged from the $9.2 million for the third quarter 2022.

Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation

Retrieved on: 
Wednesday, February 1, 2023
MBA, Health care in Sweden, Insurance, Safety, MD, FACOG, Norelgestromin/ethinylestradiol, EHR, Database, Birth, Embolism, Agile, VTE, ATE, Health information management, Partnership, PK, FDA, Ethinylestradiol, LNG, Thrombosis, PLOS, Growth, PMC, Woman, PMR, Therapy, Pharmaceutical industry, Birth control, Contraceptive patch

PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today provided an update on the Twirla® post-marketing studies and status of its ongoing evaluation of the Company’s pipeline.

Key Points: 
  • PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today provided an update on the Twirla® post-marketing studies and status of its ongoing evaluation of the Company’s pipeline.
  • Upon Twirla’s approval, Agile also agreed to an FDA-requested post-marketing commitment study to assess the residual drug content and strength of Twirla (PMC).
  • As previously disclosed, all work on Agile’s pipeline has been halted since 2021 as the Company concentrates its efforts the commercialization of Twirla.
  • “Our primary focus since the launch of Twirla has been the commercial growth of Twirla.

Agile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial Plan

Retrieved on: 
Monday, January 9, 2023
Therapy, Planned Parenthood, Telehealth, Growth, Patient, Parenthood, Agile, Physician, Pharmaceutical industry, Contraceptive patch

PRINCETON, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today provided an update on Twirla for 2022 and its commercial plan for 2023.

Key Points: 
  • PRINCETON, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today provided an update on Twirla for 2022 and its commercial plan for 2023.
  • Twirla factory sales for the fourth quarter 2022 are expected to be approximately 42,200 total cycles, a 30% increase from the 33,282 total cycles reported for the third quarter 2022.
  • “Our first commercial product, Twirla, demonstrated accelerated growth in the second half of 2022 and now we are excited to enter 2023 with strong growth momentum,” said Agile Therapeutics’ Chairman and Chief Executive Officer Al Altomari.
  • Based on its commercial plan for 2023, the Company expects increased revenue contributions from the Twirla business in 2023 and full year net revenue to be in the range of $25-$30 million.